Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953891 | 1.00 | MAPT (0.59) | MAPTCYP3A4ALDH1A1KDM4EGAA | |
| SCHEMBL7838197 | 0.83 | ALDH1A1 (0.63) | MAPTCYP3A4ALDH1A1KDM4EGAA | |
| SCHEMBL6402986 | 0.82 | MAPT (0.59) | MAPTCYP3A4ALDH1A1KDM4EGAA | |
| SCHEMBL18383120 | 0.79 | MAPT (0.69) | MAPTCYP3A4ALDH1A1KDM4EGAA | |
| SCHEMBL5460837 | 0.79 | ALDH1A1 (0.44) | MAPTCYP3A4ALDH1A1KDM4EGAA | |
| SCHEMBL28115779 | 0.78 | KDM4E (0.42) | MAPTCYP3A4ALDH1A1KDM4EGAA | |
| SCHEMBL28283806 | 0.77 | CNR1 (0.55) | — | |
| SCHEMBL669111 | 0.77 | HTT (0.73) | MAPTCYP3A4ALDH1A1KDM4EGAA | |
| SCHEMBL12355450 | 0.77 | CHRNB2 (0.60) | MAPTCYP3A4ALDH1A1KDM4EGAA | |
| SCHEMBL20299611 | 0.77 | KEAP1 (0.47) | MAPTALDH1A1KDM4EGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-20230070370-A1 | PROCESS FOR THE PREPARATION OF PANOBINOSTAT | FLAMMA SPA (IT) | 2023-03-09 | — | — | US | disclosed |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-10-27 | — | — | US | disclosed |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-03-26 | — | — | US | disclosed |
| EP-3558980-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2019-10-30 | — | — | EP | disclosed |
| CN-109106713-A | Indole-3-carbinol, di-indole methyl hydride and its derivative are preparing the application in treating organs graft-rejection drug | 黄冈昌耀电力器材有限公司 | 2019-01-01 | — | — | CN | disclosed |
| WO-2018115275-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-06-28 | — | — | WO | disclosed |
| CN-106344563-A | Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating lupus erythematosus | 安徽四正医药科技有限公司 | 2017-01-25 | — | — | CN | disclosed |
| CN-106344564-A | Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating hair follicle keratosis | 安徽四正医药科技有限公司 | 2017-01-25 | — | — | CN | disclosed |
| EP-2260020-B1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20090076029-A1 | Compounds and Methods for Treating Obesity | PALATIN TECHNOLOGIES, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1622618-A4 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008076954-A2 | HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076954-A2 | HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| CN-1816337-A | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES INC (US) | 2006-08-09 | — | — | CN | disclosed |
| EP-1622618-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | Palatin Technologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224957-A1 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076029-A1 | Compounds and Methods for Treating Obesity | MC4R, MC3R, MC1R | MAPT 3703/4885CYP3A4 3608/4885ALDH1A1 1607/4885 |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | NISCH, TK2, FDPS | MAPT 4584/4885CYP3A4 1775/4885ALDH1A1 1658/4885 |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | MC1R, MC3R, MC5R | MAPT 1287/4885CYP3A4 2965/4885ALDH1A1 4174/4885 |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | NISCH, TK2, FDPS | MAPT 4584/4885CYP3A4 1775/4885ALDH1A1 1658/4885 |
| US-20040224957-A1 | Melanocortin receptor-specific compounds | MC1R, MC5R, MC3R | MAPT 1523/4885CYP3A4 2117/4885ALDH1A1 3502/4885 |
| US-20230070370-A1 | PROCESS FOR THE PREPARATION OF PANOBINOSTAT | HDAC3, PTMA, EZH2 | MAPT 4246/4885CYP3A4 52/4885ALDH1A1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.